China Infliximab Market Survey Report 2022: Sales Volume and Value Expected to Decline in 2022 as Chinese Government Implements Strict ‘Zero Momentum COVID-19’ Policy – ResearchAndMarkets.com

0

DUBLIN–(BUSINESS WIRE)–The “Chinese Infliximab Market Investigation Report 2022-2031” report has been added to from ResearchAndMarkets.com offer.

According to this market research, since infliximab entered the Chinese market in 2007, its sales have been on an upward trend. However, sales in China are suboptimal compared to global sales.

The main reason is that most patients in China cannot afford the high price. After the inclusion of infliximab in the national medical insurance in 2019, sales increased by approximately 18.9% in 2020 and reached CNY 335.89 million in 2021. The CAGR of sales value of infliximab in China is around 19.0% from 2017 to 2021.

Infliximab was developed by Johnson & Johnson. In 2007, infliximab entered the Chinese market. The Chinese infliximab market is completely dominated by Janssen, a Johnson & Johnson company, until 2021. Two local Chinese companies, Taizhou Mabtech Pharmaceutical Co., Ltd. and Hisun Biopharmaceutical Co., Ltd. are launching infliximab in 2021, making Janssen’s infliximab a challenge in the Chinese market.

Infliximab is a chimeric human-mouse IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-a) (composed of human IgG1 constant region and mouse variable region). It is used to treat various autoimmune diseases, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis.

According to this market research and interviews with experts, the analyst sees different trends in 2022 and from 2023 to 2026 in the Chinese infliximab market.

The volume and value of infliximab sales in China are expected to decline in 2022 as the Chinese government implements a strict “COVID-19 dynamic zeroing” policy that will prevent many healthcare institutions in China from operating normally.

The Chinese government is expected to relax the COVID-19 control policy from the beginning of 2023, and thus the sales volume and sales value of infliximab in China will show recovery growth from 2023-2026.

Topics Covered:

  • The impact of COVID-19 on the Chinese infliximab market

  • Infliximab sales value in China 2017-2021

  • Competitive landscape of Chinese infliximab market

  • Infliximab price in China

  • Infliximab Price in China by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese infliximab market

  • China infliximab market outlook from 2022 to 2026

Main topics covered:

1 Relevant infliximab concepts

1.1 Indications for infliximab

1.2 Development of infliximab in China

1.3 Government approval of infliximab in China

1.4 The impact of COVID-19 on infliximab sales in China

2 China Infliximab Sales, 2017-2021

2.1 Infliximab Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Region

2.2 Infliximab Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 China Infliximab Sales by Dosage Form, 2017-2021

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 Analysis of Infliximab Key Manufacturers in China, 2017-2021

3.1 Infliximab Key Manufacturers Market Share Analysis

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 Janssen Biologics BV

3.2.1 Company profile

3.2.2 REMICADE (Janssen Infliximab) Sales in China

4 infliximab prices for different manufacturers in China, 2021-2022

4.1 Janssen Biologics BV (REMICADE)

5 China Infliximab Drug Market Outlook, 2022- 2031

5.1 Influencing Factors of China Infliximab Market Development

5.1.1 The impact of COVID-19 on the Chinese infliximab market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

For more information on this report, visit https://www.researchandmarkets.com/r/vn1vhg

Share.

Comments are closed.